title: [Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
abstract: Although allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment option for multiple myeloma (MM), it is not recognized as a standard of care because of the high associated incidences of both treatment related mortality and relapse. We administered lenalidomide (Len) as maintenance therapy for patients with MM undergoing allo-SCT who were at high risk of disease relapse. Graft-versus-host disease was induced by Len administration in two patients, but was manageable with dose reduction. Although Len has a direct anti-myeloma effect and can also induce tumor immunity against residual myeloma cells, it is important to identify how to optimize the safety and the effects of Len administration after allo-SCT. Further accumulation of data including those from prospective clinical trials is urgently needed.
authors.affiliation: Division of Hematology, Japanese Red Cross Medical Center.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
authors.forename: Sumito
authors.initials: S
authors.lastname: Shingaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikeda
authors.forename: Kanji
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Sohsuke
authors.initials: S
authors.lastname: Meshitsuka
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yoshiki
authors.forename: Yu
authors.initials: Y
authors.lastname: Abe
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D006086:Graft vs Host Disease / Q000139:chemically induced*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D012008:Recurrence; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*; D014184:Transplantation, Homologous
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide